| 000 | 01860 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517195904.0 | ||
| 264 | 0 | _c20190624 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1365-2125 | ||
| 024 | 7 |
_a10.1111/bcp.13531 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWallerstedt, Susanna M | |
| 245 | 0 | 0 |
_aBalancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _c06 2018 |
||
| 300 |
_a1146-1155 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Systematic Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDecision Support Techniques |
| 650 | 0 | 4 |
_aDrug Approval _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aDrug Costs _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aEndpoint Determination |
| 650 | 0 | 4 |
_aEvidence-Based Medicine _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Policy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsurance, Health, Reimbursement _xeconomics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aPolicy Making |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aResearch Design _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aSweden |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUncertainty |
| 650 | 0 | 4 | _aUnited Kingdom |
| 650 | 0 | 4 |
_aValue-Based Health Insurance _xeconomics |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aHenriksson, Martin | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 84 _gno. 6 _gp. 1146-1155 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bcp.13531 _zAvailable from publisher's website |
| 999 |
_c28025107 _d28025107 |
||